Alectinib(CAS: 1256580-46-7)

Alectinib (CAS: 1256580-46-7) is regulated under the REACH regulations in the European Union, which requires manufacturers and importers to register substances if they exceed the tonnage threshold. In the USA, the FDA may require specific regulatory submissions and approvals. Additionally, it is subject to GHS classification for hazardous properties and may be regulated by the EPA for environmental and safety standards.

Alternatives to Alectinib include other anaplastic lymphoma kinase (ALK) inhibitors such as crizotinib and ceritinib. These compounds may be used in the synthesis of Alectinib as they share similar mechanisms of action. Other synthetic strategies may involve using isomers or analogs that offer improved efficacy or reduced side effects.

The market for Alectinib is growing due to its efficacy in treating ALK-positive non-small cell lung cancer. Research trends focus on its use in combination therapies and its potential in treating other cancers. Market trends also reflect increasing demand for precision oncology treatments.

Waste containing Alectinib should be collected in suitable containers and stored in a secure, well-ventilated area until disposal. It should be incinerated or disposed of through a professional waste disposal service that follows environmental protection standards. Proper labeling and documentation are essential to comply with regulatory requirements and ensure safety during disposal.